Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer

Jennifer M. Specht, Brenda F. Kurland, Susan K. Montgomery, Lisa K. Dunnwald, Robert K. Doot, Julie R. Gralow, Georgina K. Ellis, Hannah M. Linden, Robert B Livingston, Kimberly H. Allison, Erin K. Schubert, David A. Mankoff

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Purpose: Dynamic positron emission tomography (PET) imaging can identify patterns of breast cancer metabolism and perfusion in patients receiving neoadjuvant chemotherapy (NC) that are predictive of response. This analysis examines tumor metabolism and perfusion by tumor subtype. Experimental Design: Tumor subtype was defined by immunohistochemistry in 71 patients with locally advanced breast cancer undergoing NC. Subtype was defined as luminal [estrogen receptor (ER)/progesterone receptor (PR) positive], triple negative [TN; ER/PR negative, human epidermal growth factor receptor 2 (HER2) negative], and HER2 (ER/PR negative, HER2 overexpressing). Metabolic rate (MRFDG) and blood flow (BF) were calculated from PET imaging before NC. Pathologic complete response (pCR) to NC was classified as pCR versus other. Results: Twenty-five (35%) of 71 patients hadTNtumors; 6 (8%) were HER2 and 40 (56%) were luminal. MRFDG for TN tumors was on average 67% greater than for luminal tumors (95% confidence interval, 9-156%) and average MRFDG/BF ratio was 53% greater in TN compared with luminal tumors (95% confidence interval, 9-114%; P < 0.05 for both). Average BF levels did not differ by subtype (P = 0.73). Most luminal tumors showed relatively low MRFDG and BF (and did not achieve pCR); high MRFDG was generally matched with high BF in luminal tumors and predicted pCR. This was not true in TN tumors. Conclusion: The relationship between breast tumor metabolism and perfusion differed by subtype. The high MRFDG/BF ratio that predicts poor response to NC was more common in TN tumors. Metabolism and perfusion measures may identify subsets of tumors susceptible and resistant to NC and may help direct targeted therapy.

Original languageEnglish (US)
Pages (from-to)2803-2810
Number of pages8
JournalClinical Cancer Research
Volume16
Issue number10
DOIs
StatePublished - May 15 2010

Fingerprint

Positron-Emission Tomography
Breast Neoplasms
Neoplasms
Drug Therapy
Progesterone Receptors
Perfusion
Estrogen Receptors
Confidence Intervals
Research Design
Immunohistochemistry
human ERBB2 protein

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Specht, J. M., Kurland, B. F., Montgomery, S. K., Dunnwald, L. K., Doot, R. K., Gralow, J. R., ... Mankoff, D. A. (2010). Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clinical Cancer Research, 16(10), 2803-2810. https://doi.org/10.1158/1078-0432.CCR-10-0026

Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. / Specht, Jennifer M.; Kurland, Brenda F.; Montgomery, Susan K.; Dunnwald, Lisa K.; Doot, Robert K.; Gralow, Julie R.; Ellis, Georgina K.; Linden, Hannah M.; Livingston, Robert B; Allison, Kimberly H.; Schubert, Erin K.; Mankoff, David A.

In: Clinical Cancer Research, Vol. 16, No. 10, 15.05.2010, p. 2803-2810.

Research output: Contribution to journalArticle

Specht, JM, Kurland, BF, Montgomery, SK, Dunnwald, LK, Doot, RK, Gralow, JR, Ellis, GK, Linden, HM, Livingston, RB, Allison, KH, Schubert, EK & Mankoff, DA 2010, 'Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer', Clinical Cancer Research, vol. 16, no. 10, pp. 2803-2810. https://doi.org/10.1158/1078-0432.CCR-10-0026
Specht, Jennifer M. ; Kurland, Brenda F. ; Montgomery, Susan K. ; Dunnwald, Lisa K. ; Doot, Robert K. ; Gralow, Julie R. ; Ellis, Georgina K. ; Linden, Hannah M. ; Livingston, Robert B ; Allison, Kimberly H. ; Schubert, Erin K. ; Mankoff, David A. / Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. In: Clinical Cancer Research. 2010 ; Vol. 16, No. 10. pp. 2803-2810.
@article{5dfcff27f25f45ffa5a0269d7af3bde2,
title = "Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer",
abstract = "Purpose: Dynamic positron emission tomography (PET) imaging can identify patterns of breast cancer metabolism and perfusion in patients receiving neoadjuvant chemotherapy (NC) that are predictive of response. This analysis examines tumor metabolism and perfusion by tumor subtype. Experimental Design: Tumor subtype was defined by immunohistochemistry in 71 patients with locally advanced breast cancer undergoing NC. Subtype was defined as luminal [estrogen receptor (ER)/progesterone receptor (PR) positive], triple negative [TN; ER/PR negative, human epidermal growth factor receptor 2 (HER2) negative], and HER2 (ER/PR negative, HER2 overexpressing). Metabolic rate (MRFDG) and blood flow (BF) were calculated from PET imaging before NC. Pathologic complete response (pCR) to NC was classified as pCR versus other. Results: Twenty-five (35{\%}) of 71 patients hadTNtumors; 6 (8{\%}) were HER2 and 40 (56{\%}) were luminal. MRFDG for TN tumors was on average 67{\%} greater than for luminal tumors (95{\%} confidence interval, 9-156{\%}) and average MRFDG/BF ratio was 53{\%} greater in TN compared with luminal tumors (95{\%} confidence interval, 9-114{\%}; P < 0.05 for both). Average BF levels did not differ by subtype (P = 0.73). Most luminal tumors showed relatively low MRFDG and BF (and did not achieve pCR); high MRFDG was generally matched with high BF in luminal tumors and predicted pCR. This was not true in TN tumors. Conclusion: The relationship between breast tumor metabolism and perfusion differed by subtype. The high MRFDG/BF ratio that predicts poor response to NC was more common in TN tumors. Metabolism and perfusion measures may identify subsets of tumors susceptible and resistant to NC and may help direct targeted therapy.",
author = "Specht, {Jennifer M.} and Kurland, {Brenda F.} and Montgomery, {Susan K.} and Dunnwald, {Lisa K.} and Doot, {Robert K.} and Gralow, {Julie R.} and Ellis, {Georgina K.} and Linden, {Hannah M.} and Livingston, {Robert B} and Allison, {Kimberly H.} and Schubert, {Erin K.} and Mankoff, {David A.}",
year = "2010",
month = "5",
day = "15",
doi = "10.1158/1078-0432.CCR-10-0026",
language = "English (US)",
volume = "16",
pages = "2803--2810",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer

AU - Specht, Jennifer M.

AU - Kurland, Brenda F.

AU - Montgomery, Susan K.

AU - Dunnwald, Lisa K.

AU - Doot, Robert K.

AU - Gralow, Julie R.

AU - Ellis, Georgina K.

AU - Linden, Hannah M.

AU - Livingston, Robert B

AU - Allison, Kimberly H.

AU - Schubert, Erin K.

AU - Mankoff, David A.

PY - 2010/5/15

Y1 - 2010/5/15

N2 - Purpose: Dynamic positron emission tomography (PET) imaging can identify patterns of breast cancer metabolism and perfusion in patients receiving neoadjuvant chemotherapy (NC) that are predictive of response. This analysis examines tumor metabolism and perfusion by tumor subtype. Experimental Design: Tumor subtype was defined by immunohistochemistry in 71 patients with locally advanced breast cancer undergoing NC. Subtype was defined as luminal [estrogen receptor (ER)/progesterone receptor (PR) positive], triple negative [TN; ER/PR negative, human epidermal growth factor receptor 2 (HER2) negative], and HER2 (ER/PR negative, HER2 overexpressing). Metabolic rate (MRFDG) and blood flow (BF) were calculated from PET imaging before NC. Pathologic complete response (pCR) to NC was classified as pCR versus other. Results: Twenty-five (35%) of 71 patients hadTNtumors; 6 (8%) were HER2 and 40 (56%) were luminal. MRFDG for TN tumors was on average 67% greater than for luminal tumors (95% confidence interval, 9-156%) and average MRFDG/BF ratio was 53% greater in TN compared with luminal tumors (95% confidence interval, 9-114%; P < 0.05 for both). Average BF levels did not differ by subtype (P = 0.73). Most luminal tumors showed relatively low MRFDG and BF (and did not achieve pCR); high MRFDG was generally matched with high BF in luminal tumors and predicted pCR. This was not true in TN tumors. Conclusion: The relationship between breast tumor metabolism and perfusion differed by subtype. The high MRFDG/BF ratio that predicts poor response to NC was more common in TN tumors. Metabolism and perfusion measures may identify subsets of tumors susceptible and resistant to NC and may help direct targeted therapy.

AB - Purpose: Dynamic positron emission tomography (PET) imaging can identify patterns of breast cancer metabolism and perfusion in patients receiving neoadjuvant chemotherapy (NC) that are predictive of response. This analysis examines tumor metabolism and perfusion by tumor subtype. Experimental Design: Tumor subtype was defined by immunohistochemistry in 71 patients with locally advanced breast cancer undergoing NC. Subtype was defined as luminal [estrogen receptor (ER)/progesterone receptor (PR) positive], triple negative [TN; ER/PR negative, human epidermal growth factor receptor 2 (HER2) negative], and HER2 (ER/PR negative, HER2 overexpressing). Metabolic rate (MRFDG) and blood flow (BF) were calculated from PET imaging before NC. Pathologic complete response (pCR) to NC was classified as pCR versus other. Results: Twenty-five (35%) of 71 patients hadTNtumors; 6 (8%) were HER2 and 40 (56%) were luminal. MRFDG for TN tumors was on average 67% greater than for luminal tumors (95% confidence interval, 9-156%) and average MRFDG/BF ratio was 53% greater in TN compared with luminal tumors (95% confidence interval, 9-114%; P < 0.05 for both). Average BF levels did not differ by subtype (P = 0.73). Most luminal tumors showed relatively low MRFDG and BF (and did not achieve pCR); high MRFDG was generally matched with high BF in luminal tumors and predicted pCR. This was not true in TN tumors. Conclusion: The relationship between breast tumor metabolism and perfusion differed by subtype. The high MRFDG/BF ratio that predicts poor response to NC was more common in TN tumors. Metabolism and perfusion measures may identify subsets of tumors susceptible and resistant to NC and may help direct targeted therapy.

UR - http://www.scopus.com/inward/record.url?scp=77952350449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952350449&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-0026

DO - 10.1158/1078-0432.CCR-10-0026

M3 - Article

C2 - 20460489

AN - SCOPUS:77952350449

VL - 16

SP - 2803

EP - 2810

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -